EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 22 / No 4 (Avril 2006) Med Sci (Paris), 22 4 (2006) 381-388 References
Free Access
Issue
Med Sci (Paris)
Volume 22, Number 4, Avril 2006
Page(s) 381 - 388
Section M/S revues
DOI https://doi.org/10.1051/medsci/2006224381
Published online 15 April 2006
  1. Cheung PC, Salt IP, Davies SP, et al. Characterization of AMP-activated protein kinase gamma-subunit isoforms and their role in AMP binding. Biochem J 2000; 346 : 659–69. [Google Scholar]
  2. Salt I, Celler JW, Hawley SA, et al. AMP-activated protein kinase : greater AMP dependence, and preferential nuclear localization, of complexes containing the alpha2 isoform. Biochem J 1998; 334 : 177–87. [Google Scholar]
  3. Mahlapuu M, Johansson C, Lindgren K, et al. Expression profiling of the gamma-subunit isoforms of AMP-activated protein kinase suggests a major role for gamma3 in white skeletal muscle. Am J Physiol Endocrinol Metab 2004; 286 : E194–200. [Google Scholar]
  4. Wojtaszewski JF, Birk JB, Frosig C, et al. 5’AMP activated protein kinase expression in human skeletal muscle : effects of strength training and type 2 diabetes. J Physiol 2005; 564 : 563–73. [Google Scholar]
  5. Kawaguchi T, Osatomi K, Yamashita H, et al. Mechanism for fatty acid “sparing” effect on glucose-induced transcription : regulation of carbohydrate-responsive element-binding protein by AMP-activated protein kinase. J Biol Chem 2002; 277 : 3829–35. [Google Scholar]
  6. Koo SH, Flechner L, Qi L, et al. The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. Nature 2005; 437 : 1109–11. [Google Scholar]
  7. Hong YH, Varanasi US, Yang W, Leff T. AMP-activated protein kinase regulates HNF4alpha transcriptional activity by inhibiting dimer formation and decreasing protein stability. J Biol Chem 2003; 278 : 27495–501. [Google Scholar]
  8. Barthel A, Schmoll D, Kruger KD, et al. Regulation of the forkhead transcription factor FKHR (FOXO1a) by glucose starvation and AICAR, an activator of AMP-activated protein kinase. Endocrinology 2002; 143 : 3183–6. [Google Scholar]
  9. Hudson ER, Pan DA, James J, et al. A novel domain in AMP-activated protein kinase causes glycogen storage bodies similar to those seen in hereditary cardiac arrhythmias. Curr Biol 2003; 13 : 861–6. [Google Scholar]
  10. Polekhina G, Gupta A, Michell BJ, et al. AMPK beta subunit targets metabolic stress sensing to glycogen. Curr Biol 2003; 13 : 867–71. [Google Scholar]
  11. Scott JW, Hawley SA, Green KA, et al. CBS domains form energy-sensing modules whose binding of adenosine ligands is disrupted by disease mutations. J Clin Invest 2004; 113 : 274–84. [Google Scholar]
  12. Woods A, Johnstone SR, Dickerson K, et al. LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr Biol 2003; 13 : 2004–8. [Google Scholar]
  13. Hawley SA, Boudeau J, Reid JL, et al. Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. J Biol 2003; 2 : 28. [Google Scholar]
  14. Shaw RJ, Kosmatka M, Bardeesy N, et al. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci USA 2004; 101 : 3329–35. [Google Scholar]
  15. Woods A, Dickerson K, Heath R, et al. C(Ca2+)/calmodulin-dependent protein kinase kinase-beta acts upstream of AMP-activated protein kinase in mammalian cells. Cell Metab 2005; 2 : 21–33. [Google Scholar]
  16. Hawley SA, Pan DA, Mustard KJ, et al. Calmodulin-dependent protein kinase kinase-beta is an alternative upstream kinase for AMP-activated protein kinase. Cell Metab 2005; 2 : 9–19. [Google Scholar]
  17. Foretz M, Carling D, Guichard C, et al. AMP-activated protein kinase inhibits the glucose-activated expression of fatty acid synthase gene in rat hepatocytes. J Biol Chem 1998; 273 : 14767–71. [Google Scholar]
  18. Leclerc I, Lenzner C, Gourdon L, et al. Hepatocyte nuclear factor-4alpha involved in type 1 maturity-onset diabetes of the young is a novel target of AMP-activated protein kinase. Diabetes 2001; 50 : 1515–21. [Google Scholar]
  19. Foretz M, Ancellin N, Andreelli F, et al. Short-term overexpression of a constitutively active form of AMP-activated protein kinase in the liver leads to mild hypoglycemia and fatty liver. Diabetes 2005; 54 : 1331–9. [Google Scholar]
  20. Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001; 108 : 1167–74. [Google Scholar]
  21. Minokoshi Y, Kim YB, Peroni OD, et al. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 2002; 415 : 339–43. [Google Scholar]
  22. Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002; 8 : 1288–95. [Google Scholar]
  23. Tomas E, Tsao TS, Saha AK, et al. Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain : acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc Natl Acad Sci USA 2002; 99 : 16309–13. [Google Scholar]
  24. Iglesias MA, Ye JM, Frangioudakis G, et al. AICAR administration causes an apparent enhancement of muscle and liver insulin action in insulin-resistant high-fat-fed rats. Diabetes 2002; 51 : 2886–94. [Google Scholar]
  25. Zong H, Ren JM, Young LH, et al. AMP kinase is required for mitochondrial biogenesis in skeletal muscle in response to chronic energy deprivation. Proc Natl Acad Sci USA 2002; 99 : 15983–7. [Google Scholar]
  26. Hayashi T, Hirshman MF, Kurth EJ, et al. Evidence for 5’ AMP-activated protein kinase mediation of the effect of muscle contraction on glucose transport. Diabetes 1998; 47 : 1369–73. [Google Scholar]
  27. Russell RR, 3rd, Bergeron R, Shulman GI, Young LH. Translocation of myocardial GLUT-4 and increased glucose uptake through activation of AMPK by AICAR. Am J Physiol 1999; 277 : H643–9. [Google Scholar]
  28. Jorgensen SB, Viollet B, Andreelli F, et al. Knockout of the alpha2 but not alpha1 5’-AMP-activated protein kinase isoform abolishes 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranosidebut not contraction-induced glucose uptake in skeletal muscle. J Biol Chem 2004; 279 : 1070–9. [Google Scholar]
  29. Marsin AS, Bertrand L, Rider MH, et al. Phosphorylation and activation of heart PFK-2 by AMPK has a role in the stimulation of glycolysis during ischaemia. Curr Biol 2000; 10 : 1247–55. [Google Scholar]
  30. Bergeron R, Previs SF, Cline GW, et al. Effect of 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside infusion on in vivo glucose and lipid metabolism in lean and obese Zucker rats. Diabetes 2001; 50 : 1076–82. [Google Scholar]
  31. Viollet B, Andreelli F, Jorgensen SB, et al. The AMP-activated protein kinase alpha2 catalytic subunit controls whole-body insulin sensitivity. J Clin Invest 2003; 111 : 91–8. [Google Scholar]
  32. Villena JA, Viollet B, Andreelli F, et al. Induced adiposity and adipocyte hypertrophy in mice lacking the AMP-activated protein kinase-alpha2 subunit. Diabetes 2004; 53 : 2242–9. [Google Scholar]
  33. Fryer LG, Parbu-Patel A, Carling D. The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem 2002; 277 : 25226–32. [Google Scholar]
  34. Minokoshi Y, Alquier T, Furukawa N, et al. AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature 2004; 428 : 569–74. [Google Scholar]
  35. Andersson U, Filipsson K, Abbott CR, et al. AMP-activated protein kinase plays a role in the control of food intake. J Biol Chem 2004; 279 : 12005–8. [Google Scholar]
  36. Kola B, Hubina E, Tucci SA, et al. Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effects via AMP-activated protein kinase. J Biol Chem 2005;280 : 25196–201. [Google Scholar]
  37. Kim MS, Park JY, Namkoong C, et al. Anti-obesity effects of alpha-lipoic acid mediated by suppression of hypothalamic AMP-activated protein kinase. Nat Med 2004; 10 : 727–33. [Google Scholar]
  38. Kim EK, Miller I, Aja S, et al. C75, a fatty acid synthase inhibitor, reduces food intake via hypothalamic AMP-activated protein kinase. J Biol Chem 2004; 279 : 19970–6. [Google Scholar]
  39. Namkoong C, Kim MS, Jang PG, et al. Enhanced hypothalamic AMP-activated protein kinase activity contributes to hyperphagia in diabetic rats. Diabetes 2005; 54 : 63–8. [Google Scholar]
  40. Sambandam N, Lopaschuk GD. AMP-activated protein kinase (AMPK) control of fatty acid and glucose metabolism in the ischemic heart. Prog Lipid Res 2003; 42 : 238–56. [Google Scholar]
  41. Xing Y, Musi N, Fujii N, et al. Glucose metabolism and energy homeostasis in mouse hearts overexpressing dominant negative alpha2 subunit of AMP-activated protein kinase. J Biol Chem 2003; 278 : 28372–7. [Google Scholar]
  42. Russell RR 3rd, Li J, Coven DL, et al. AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. J Clin Invest 2004; 114 : 495–503. [Google Scholar]
  43. Shibata R, Sato K, Pimentel DR, et al. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat Med 2005; 11 : 1096–103. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.